Phase I trial of a heat-conditioned tumor lysate vaccine (TRIMELVax) in anti-PD-1 refractory melanoma: safety and immunological aspects (NCT06556004)

British Journal of Cancer 2026 Open access

Read full text
Authors: Roberto Estay, Analía Cortés, Bettina Müller, Fabián Tempio, Consuelo Merino, Camila Fuentes, Andrea Rebolledo, Nicole Ramírez, Patricia Contalba, Karina Bustos, Cristián Pereda, M Alejandra Gleisner
+9 more Iván Flores, Fermín Eduardo González, Andrés Tittarelli, Adnane Achour, Sofía Hidalgo, Álvaro Lladser, Marı́a Inés Becker, Flavio Salazar-Onfray, Mercedes Natalia López
DOI: 10.1038/s41416-026-03459-1
Cited by: 1
References: 39

Fields of Study & Subjects

Immunotherapy and Immune Responses Cancer Immunotherapy and Biomarkers vaccines and immunoinformatics approaches

Publication details

Journal / source
British Journal of Cancer
Publisher
Springer Science and Business Media LLC
Volume
135
Issue
3
Pages
436–444
Publication date
30 April 2026
Language
EN